The Board of Directors of PIQUR Therapeutics AG is pleased to announce the appointment of Dr. Melanie Rolli as Chief Executive Officer with immediate effect. Dr. Rolli joined PIQUR in 2017 as Chief Medical Officer and took on additional responsibilities as Chief Operating Officer in 2018. Richard Laube will remain serving as Chairman of PIQUR’s Board of Directors.
Mr. Laube highlights the outstanding efforts of Dr. Rolli in driving PIQUR’s business. “Under Dr. Rolli’s leadership as Chief Operating Officer, PIQUR has refocused the bimiralisib oral cancer clinical development program towards a promising individualised therapy treating patients with head and neck cancer harboring specific mutations. Furthermore, she has been instrumental in accelerating the development of the bimiralisib’s topical application with the completion of the preclinical program, and shortly entering Phase 1 human trials to treat cutaneous T-cell lymphoma. In addition, Dr. Rolli has worked to significantly reduce PIQUR’s operating expenses while simultaneously improving the quality and motivation of PIQUR’s associates. The company is on track with all of its strategic initiatives,” said Mr. Laube. “Dr. Rolli has the unanimous support of our Board to steer PIQUR towards fully realising the potential of our pipeline for personalised targeted therapy. Her visionary leadership will create additional value for patients, shareholders and employees,” stated the Chairman further.
Founded in 2011, PIQUR is a Basel-based clinical stage biotech company dedicated to drug development of targeted therapy in various oncological and dermatological indications.